An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.

@article{Sharman2015AnOP,
  title={An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.},
  author={Jeff P. Sharman and Michael J. Hawkins and Kathryn S. Kolibaba and Michael A Boxer and Leonard M Klein and Meihua Wu and Jing Hu and Steve Abella and Chris A. Yasenchak},
  journal={Blood},
  year={2015},
  volume={125 15},
  pages={2336-43}
}
Small-molecule inhibitors of kinases involved in B-cell receptor signaling are an important advance in managing lymphoid malignancies. Entospletinib (GS-9973) is an oral, selective inhibitor of spleen tyrosine kinase. This multicenter, phase 2 study enrolled subjects with relapsed or refractory chronic lymphocytic leukemia (CLL; n = 41) or non-Hodgkin lymphoma (n = 145). Participants received 800 mg entospletinib twice daily. We report efficacy outcomes in the CLL cohort (n = 41) and safety… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
52 Citations
19 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 52 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL)

  • PM Barr, GB Saylors, SEF Spurgeon
  • J Clin Oncol
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…